CoChat

Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer’s disease

Open access

Published version of a preprint

The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.

Abstract

Background: Identifying novel therapeutic targets is crucial for the successful development of drugs. However, the cost to experimentally identify therapeutic targets is huge and only approximately 400 genes are targets for FDA-approved drugs. As a result, it is inevitable to develop powerful computational tools that can identify potential novel therapeutic targets. Fortunately, the human protein-protein interaction network (PIN) could be a useful resource to achieve this objective. Methods: In this study, we developed a deep learning-based computational framework that extracts low-dimensional representations of high-dimensional PIN data. Our computational framework uses latent features and state-of-the-art machine learning techniques to infer potential drug target genes. Results: We applied our computational framework to prioritize novel putative target genes for Alzheimer’s disease and successfully identified key genes that may serve as novel therapeutic targets (e.g., DLG4, EGFR, RAC1, SYK, PTK2B, SOCS1). Furthermore, based on these putative targets, we could infer repositionable candidate-compounds for the disease (e.g., tamoxifen, bosutinib, and dasatinib). Conclusions: Our deep learning-based computational framework could be a powerful tool to efficiently prioritize new therapeutic targets and enhance the drug repositioning strategy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-021-00826-3

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Computational analysis pipeline for drug target prioritization. (Step 1) Our computational framework employed genome-wide PINs and information of drug targets obtained from public domain databases. (Step 2) The framework is based on a deep autoencoder to extract low-dimensional latent features from high-dimensional PIN. (Step 3) By using features from step 2 and a target gene list for a specific disease, we generated 100 datasets to train the 100 classifier models. By using the 100 datasets and the state-of-the-art machine learning techniques (SMOTE and Xgboost), we build 100 classifier models to infer potential drug targets. (Step 4) We applied the classifier models to all unknown drug-target genes in the PIN to prioritize potential drug target genes
Fig. 1 Computational analysis pipeline for drug target prioritization. (Step 1) Our computational framework employed genome-wide PINs and information of drug targets obtained from public domain databases. (Step 2) The framework is based on a deep autoencoder to extract low-dimensional latent features from high-dimensional PIN. (Step 3) By using features from step 2 and a target gene list for a specific disease, we generated 100 datasets to train the 100 classifier models. By using the 100 datasets and the state-of-the-art machine learning techniques (SMOTE and Xgboost), we build 100 classifier models to infer potential drug targets. (Step 4) We applied the classifier models to all unknown drug-target genes in the PIN to prioritize potential drug target genesCC BY · PubMed Central
Fig. 2 Relationship between features in low-dimensional latent space by deep autoencoder and representative network metrics in the PIN. The X-axis is the latent space dimension and the Y-axis is Spearman’s correlation coefficient between a given low-dimensional feature and a given network metric (see Supplementary Figure 1 for the original data). The gray background dimensions (58, 86, 88, and 89) indicate almost no correlation to the representative network metrics. Several dimensions without the box (e.g., dimension 6 and 7) are n.a. because the encoded numerical values for all genes are zero
Fig. 2 Relationship between features in low-dimensional latent space by deep autoencoder and representative network metrics in the PIN. The X-axis is the latent space dimension and the Y-axis is Spearman’s correlation coefficient between a given low-dimensional feature and a given network metric (see Supplementary Figure 1 for the original data). The gray background dimensions (58, 86, 88, and 89) indicate almost no correlation to the representative network metrics. Several dimensions without the box (e.g., dimension 6 and 7) are n.a. because the encoded numerical values for all genes are zeroCC BY · PubMed Central
Fig. 3 Pathway enrichment analysis using GO biological database for the 187 putative targets from our computational pipeline for Alzheimer’s disease. The names of the pathways are shown on the vertical axis, and the bars on the horizontal axis represent the − log10(p value) of the corresponding pathway. Dashed lines in orange, magenta, and red indicate p value <0.05, 0.01, and 0.001, respectively
Fig. 3 Pathway enrichment analysis using GO biological database for the 187 putative targets from our computational pipeline for Alzheimer’s disease. The names of the pathways are shown on the vertical axis, and the bars on the horizontal axis represent the − log10(p value) of the corresponding pathway. Dashed lines in orange, magenta, and red indicate p value <0.05, 0.01, and 0.001, respectivelyCC BY · PubMed Central
Fig. 4 Pathway enrichment analysis using the KEGG database for 187 putative targets. The legend for this figure is the same as that for Fig. 3
Fig. 4 Pathway enrichment analysis using the KEGG database for 187 putative targets. The legend for this figure is the same as that for Fig. 3CC BY · PubMed Central
Fig. 5 Pathway enrichment analysis using the Reactome pathway for 187 putative targets. The legend for this figure is the same as that for Fig. 3
Fig. 5 Pathway enrichment analysis using the Reactome pathway for 187 putative targets. The legend for this figure is the same as that for Fig. 3CC BY · PubMed Central
Fig. 6 A method to infer potential repositionable drugs based on the putative targets derived from our computational pipeline. Step 1: We obtained the drug-target-disease network from the DrugBank database. Step 2: We mapped the associations between the putative target genes and their target diseases to infer the potential repositionable drugs for a given disease
Fig. 6 A method to infer potential repositionable drugs based on the putative targets derived from our computational pipeline. Step 1: We obtained the drug-target-disease network from the DrugBank database. Step 2: We mapped the associations between the putative target genes and their target diseases to infer the potential repositionable drugs for a given diseaseCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Research works printed but not linked: 1

  1. Van Der Maaten L, Postma E, Van den Herik J. Dimensionality reduction: a comparative. J Mach Learn Res. 2009; 10(66-71):13.

Cited by

See all 77

Metadata

Authors
Tsuji, S., Hase, T., Yachie-Kinoshita, A., Nishino, T., Ghosh, S., Kikuchi, M., Shimokawa, K., Aburatani, H., Kitano, H., & Tanaka, H.
Affiliations
  • Research Center for Advanced Science and Technology, The University of Tokyo (JP)
  • Tokyo Medical and Dental University (JP)
  • Systems Biology Institute (JP)
  • The University of Osaka (JP)
  • Center for Mathematical Modeling and Data Science, The University of Osaka (JP)
Corresponding author
  • Tsuji, Shingo
  • Hase, Takeshi
Venue
Alzheimer's Research & Therapy
Published
2021-05-03
Volume
13
Issue
1
Pages
92-92
ISSN
1758-9193 (ISSN-L)
OpenAlex
W3158891634
Cited by
75
References
62
Citations by year
2026: 12 · 2025: 16 · 2024: 20 · 2023: 15 · 2022: 10 · 2021: 2
FWCI
6.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Japan Society for the Promotion of Science (17H06107, 20K15778)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
drug target prioritization, drug repurposing, Alzheimer's disease, protein-protein interaction network, deep learning, drug target identification, latent representations, drug candidates, PSD-95, EGFR, Rac1, Syk, Pyk2, SOCS1, tamoxifen, bosutinib, dasatinib
MeSH terms
Machine Learning, Alzheimer Disease, Artificial Intelligence, Pharmaceutical Preparations, Humans, Drug Repositioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13195-021-00826-3
The paper
Tsuji, S., Hase, T., Yachie-Kinoshita, A., Nishino, T., Ghosh, S., Kikuchi, M., Shimokawa, K., Aburatani, H., Kitano, H., & Tanaka, H. (2021). Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer’s disease. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-021-00826-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.